Clinical bottom line
Idiopathic sudden sensorineural hearing loss (ISSNHL) remains a clinical emergency with evolving management strategies aiming to optimize hearing recovery. Systemic corticosteroids continue as first-line therapy, supported by robust guideline recommendations, while adjunctive treatments such as intratympanic steroids and hyperbaric oxygen therapy (HBOT) may benefit select patients. Emerging pathophysiologic phenotyping offers promise for precision medicine approaches. Safety considerations, particularly regarding corticosteroid adverse effects, are increasingly recognized. Despite advances, prognosis remains variable, underscoring the need for individualized treatment and further research (Chandrasekhar et al., 2019; Ibrahim et al., 2026; Wu et al., 2025).
What the evidence shows
The 2019 AAO-HNS Clinical Practice Guideline update by Chandrasekhar et al. remains the cornerstone reference, endorsing prompt initiation of systemic corticosteroids to improve hearing outcomes in ISSNHL. Intratympanic steroid injections are recommended as salvage therapy or primary treatment when systemic steroids are contraindicated.
Ibrahim et al. (2026) advance the concept of pathophysiologic phenotyping, identifying distinct ISSNHL subtypes based on vascular, inflammatory, or viral etiologies. This approach may guide tailored therapies in the future, though clinical application is still investigational.
Wu et al. (2025) provide a large clinical study on methylprednisolone sodium succinate, detailing adverse drug reactions and risk mitigation strategies, highlighting the importance of monitoring and patient selection to minimize corticosteroid-related complications.
Plaza et al. (2024) review systemic corticosteroid protocols, emphasizing dose, timing, and tapering regimens that balance efficacy and safety.
García Arumí et al. (2024) summarize evidence supporting HBOT as an adjunctive treatment, particularly when initiated early, noting improved hearing recovery rates in some cohorts.
Sahoo et al. (2014) and Seok et al. (2012) discuss alternative therapies such as acupuncture, though evidence remains limited and inconsistent.
Caveats and uncertainty
Heterogeneity in ISSNHL etiology and presentation complicates treatment standardization and prognostication.
High-quality randomized controlled trials comparing systemic versus intratympanic steroids, or evaluating combination therapies, are limited.
Optimal corticosteroid dosing and duration remain debated, with variable protocols reported.
HBOT availability and cost may restrict its use; evidence for its benefit is modest and best in early treatment windows.
Safety data on corticosteroids underscore the need for vigilance, especially in patients with comorbidities.
Emerging phenotyping approaches require validation before routine clinical implementation.
How this may change practice
Clinicians should continue to prioritize early systemic corticosteroid therapy, with intratympanic steroids as a valuable alternative or adjunct.
Incorporation of pathophysiologic phenotyping may eventually enable personalized treatment strategies, improving outcomes.
Enhanced awareness of corticosteroid adverse effects should prompt careful patient selection and monitoring.
HBOT may be considered in specialized centers for eligible patients, ideally within two weeks of symptom onset.
Multimodal treatment plans integrating pharmacologic and supportive therapies will likely evolve.
Ongoing research and guideline updates will refine management algorithms and prognostic tools.